3-methyl-N-[(2S)-3-oxobutan-2-yl]butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-methyl-N-[(2S)-3-oxobutan-2-yl]butanamide
• 化学式: C₉H₁₇NO₂
• 分子量: 171.24
• InChiKey: MJGORBZXLJELQX-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Substituted Morphinans and the Use Thereof
  申请人：Purdue Pharma L.P.

  公开号：US20140187573A1

  公开（公告）日：2014-07-03

  The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4a , and R 4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  本申请涉及式I化合物： 及其医药可接受的盐和溶剂化物，其中R1、R2、R3、R4a和R4b的定义如说明书中所述。本发明还涉及使用式I化合物来治疗对一或多个阿片受体调节有反应的疾病，或作为合成中间体。本发明中的某些化合物特别适用于治疗疼痛。
• US8946255B2
  申请人：——

  公开号：US8946255B2

  公开（公告）日：2015-02-03
• [EN] DOSAGE REGIME<br/>[FR] RÉGIME POSOLOGIQUE
  申请人：ADC THERAPEUTICS SA

  公开号：WO2020109251A1

  公开（公告）日：2020-06-04

  The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to particular dosage regimens for the administration of ADCs which bind to CD19 (CD19-ADCs).